LEADING ANTENNA MANUFACTURER A N T E N N A C O M P O N E N T S • Extremely tight performance tolerance • Dielectric performance of 3 – 7Dk • Ability to utilize existing injection molding machinery • High mold flow index (MFI) • On demand material delivery • Provided technical support throughout the development of multiple, highly technical materials • Formulated high quality materials that aligned with stringent specification, at a cost effective price • Provided order flexibility, allowing customer to order on demand • Collaborated across the supply chain, enabling customer to take a premium solution to market that can reduce maintenance and construction costs for end users Custom PREPERM™ Low-Loss Dielectric Formulations KEY REQUIREMENTS WHY AVIENT?

CRAFTECH® N O N - M E T A L L I C F A S T E N E R S • Corrosion resistance • Electrical isolation • Strength performance similar to competitive products made of metals • Supplied pre-colored long fiber reinforced composites for consistent appearance • Formulated an LFT solution to meet key performance needs and strength to compete against metal alternatives • Delivered custom formulated materials on- time with short lead times and in low release quantities Complēt™ Long Glass Fiber ETPU Composite KEY REQUIREMENTS WHY AVIENT?

MEDICAL DEVICE MANUFACTURER G U I D I N G C A T H E T E R • Ultra-soft hardness of about Shore 50A • Excellent extrusion performance, achieving a thickness of about 0.1 mm • Smooth surface • Certification for biocompatibility • Delivered an ultra-soft TPU that has good elasticity, abrasion, and tear resistance • Complied with ISO 10993 biocompatible properties • Offered onsite service to support rapid extrusion performance for the customer NEUSoft Thermoplastic Polyurethanes KEY REQUIREMENTS WHY AVIENT?

EUROPEAN MEDICAL DEVICE MANUFACTURER F A C E M A S K V E N T I L A T I O N V A L V E • ISO 9001 and USP VI compliant • Compatible with overmolding onto PP • Translucent and highly colorable • Soft touch • Provided valuable regulatory support and documentation, enabling faster internal trials and material qualification for this customer • Worked together with customer to select the best material from a broad portfolio of medical TPE grades • Trusted as a polymer supplier for multiple healthcare applications Dynaflex™ G2711 Thermoplastic Elastomer KEY REQUIREMENTS WHY AVIENT?

AUTOMOTIVE OEM C E N T R A L C O N S O L E P A R T • Metallic aspect • Good surface appearance • UV resistance • Cost effective alternative to paint • Offered a paint replacement solution with a molded-in-color metallic effect • Provided color matching expertise • Utilized simulation tools to predict part aspect and suggest the best injection point for process and mold optimization • Optimized formulation for metallic effects Smartbatch Combination Colorants & Additives KEY REQUIREMENTS WHY AVIENT?

Microsoft PowerPoint - Avient Q4 Earnings and 2021 Outlook PRINT AVIENT CORPORATION F O U R T H Q U A R T E R 2 0 2 0 R E S U L T S A N D 2 0 2 1 F I N A N C I A L G U I D A N C E (NYSE: AVNT) F E B R U A R Y 9 , 2 0 2 1 DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Whether an additional line at an existing manufacturing plant, or a new facility in a growing region, we ramp-up quickly and cost-efficiently. 22 Capex / Revenue 2021E (%) AVIENT IS ASSET LIGHT Avient Specialty Formulators Other Chemical/Specialty Companies 2 3 2 2 2 3 3 6 2 3 4 4 5 5 5 6 6 6 7 9 25 A vi en t A vi en t (E xc l. D is t. ) R P M P P G K W R F U L A V Y G C P IF F F M C H X L H U N E M N F O E E C L K R A S C L A S H C E G R A A LB Median: 5%Median: 3% Source: Peer data per Bloomberg market data as of February 5, 2021 Avient reflects 2021 estimated revenue of $4,100M and excludes one-time synergy capture CAPEX ($20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators.

TEMPERATURE DISTRIBUTION DIAGRAM • Test Method: FTTS-FA-010-2007 4.2 • Equipment: Thermovision • Heat Source: 500W Halogen Lamp • Heat Distance: 100 cm Surface temperature before exposure: 20.22°C Surface temperature after 10 min exposure: 33.85°C Temperature change: +13.6°C Added Cesa Fiber Additives for heat preservation TEST METHOD STANDARD REQUEST TEST RESULT GB/T30127 Far infrared radiation properties Far infrared emissivity ≥0.88 (5-14um) (Test temperature: 34°C) 0.9 Far infrared radiation temperature rise ≥ 1.4°C 9°C GB/T 18319-2019 Thermal retention with accumulated by infrared ray Maximum temperature rise ≥ 6°C 8.9°C Mean temperature rise ≥ 4.4°C (20 minutes) 5.6°C FTTS-FA-010 Infrared radiation properties & thermal retention temperature rise Average emissivity ≥ 0.8 (2-22um) (Test temperature: 25°C) 0.8 Specified heating ΔT ≥ 0.5°C (relative to the standard) +5.34°C (ΔT) GB/T 11048-2008 Method A Thermal transmittance Unit: clo Naked body: 0 Underwear: 0.04 T-shirt: 0.09 Thick sweater: 0.35 Winter coat: 0.7 All the data above are the reference value 0.625 Human Physiological Experiment Blood flow volume +12.9% Blood flow velocity +13.6% Blood oxygenation(%SpO2) +1.7% www.avient.com Copyright © 2023, Avient Corporation.

Microsoft PowerPoint - AVNT Q3 2021 Earnings Presentation - WEBSITE AVIENT CORPORATION T H I R D Q U A R T E R 2 0 2 1 R E S U LT S (NYSE: AVNT) O C T O B E R 2 8 , 2 0 2 1 DISCLAIMER 2 Forward-Looking Statements In this presentation, statements that are not reported financial results or other historical information are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. D is t. ) K W R P P G A V Y F U L R P M G C P F M C H X L H U N E C L A S H E M N C E S C L Source: Peer data per Bloomberg market data as of October 25, 2021 Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M) Avient Specialty Formulators Other Chemical/Specialty Companies Free Cash Flow Conversion (1) 2021E (%) Being asset light helps us to generate strong free cash flow that is in line with specialty formulators. With the Clariant Color business acquisition and divestment of the PP&S business, our exposure is now concentrated in less-cyclical and high-growth markets, with increased geographic diversification and a more specialized portfolio that can significantly expand EBITDA margins. 24 Avient reflects 2021 estimated EBITDA of $580M OUR VALUATION VERSUS PEERS Avient Specialty Formulators Other Chemical/Specialty Companies 11.0 18.3 16.3 15.4 14.5 11.6 11.1 36.2 28.0 24.9 13.0 11.5 11.3 10.0 9.2 8.8 7.7 6.7 A vi en t K W R P P G A V Y R P M F U L G C P A L B H X L E C L A S H F M C B N R S C L U N V R E M N C E H U N SUMMARY: WHY INVEST IN AVIENT?

AVIENT CORPORATION F I R S T Q U A R T E R 2 0 2 3 R E S U L T S (NYSE: AVNT) M AY 3 , 2 0 2 3 DISCLAIMER Forward-Looking Statements Certain statements contained in or incorporated by reference into this presentation constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Avient Specialty Formulators Other Specialty / Chemical Companies 2023E(%) 32 79 87 83 81 76 73 90 79 77 76 73 69 60 22 A vi en t K W R P P G F U L A V Y R P M F M C C E H X L A S H E C L H U N E M N S C L MULTIPLE EXPANSION Avient Specialty Formulators Other Specialty / Chemical Companies Source: Peer data per Bloomberg as of April 28, 2023 Note: Avient reflects 2023 adjusted EBITDA guidance of $530M and closing share price of $38.51. Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years. 33 EV / 2023E EBITDA Historic Multiple 6.5 8.3 9.9 14.6 13.7 13.0 11.9 8.8 18.7 17.4 11.8 10.0 9.7 9.1 8.0 7.9 A vi en t (2 01 1) A vi en t (2 01 8) A vi en t (2 02 3) K W R P P G R P M A V Y F U L E C L H X L F M C A S H S C L C E E M N H U N Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except for per share data) Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special items, to assess performance and facilitate comparability of results.

ELECTRICAL PARTS MANUFACTURER H E A V Y D U T Y C O N N E C T O R S A N D A C C E S S O R I E S • Reduce material rematching and rejection through more efficient pre-testing • Improve processing efficiencies and color consistency in highly FR-filled and high-temperature resins • Achieve regulatory compliance across multiple resin families • Gain better supply chain control to manage scarcity of key engineering resins and changing resin producers • Offered eight UL 94-recognized sites in U.S. and Canada that perform comprehensive analytical, physical and mechanical testing • Provided increased speed to market and expedited design timelines for new products using existing standardized and pre- approved color palettes • Ensured regulatory compliance and security of supply OnColor™ UL 94 Colorants KEY REQUIREMENTS WHY AVIENT AVIENT SOLUTION QUALITY + SPEED TO MARKET LEARN MORE © 2023, Avient Corporation, All Rights Reserved https://www.avient.com/products/polymer-colorants/solid-color-masterbatches/oncolor-ul94-colorants